This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Relapsing Multiple Sclerosis
and you are
over 18
years old
Phase
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).

Provided treatments

  • Drug: Rebif
  • Other: Other: Disease modifying therapies (DMT)
Tris trial is registered with FDA with number: NCT01601119. The sponsor of the trial is Merck KGaA and it is looking for 545 volunteers for the current phase.
Official trial title:
The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients